In the malignantly altered cells of Hodgkin's lymphoma, the NF-kappa-B is constantly in the cell nucleus. The reason, as the researchers discovered, is that certain, permanently activated enzymes switch off inhibitor proteins that normally retain NF-kappaB in the cell plasma. Furthermore, they were able to show that, in a portion of the patients, the inhibitors are defective due to mutations.
Up until now, Hodgkin's lymphoma was treated with radiation therapy and chemotherapy. The work of Scheidereit and Dörken has now provided the basis for the development of new therapeutic approaches. In pre-clinical studies, different substances are currently being tested as to their capability to directly or indirectly block IKK activity. It remains to be seen whether this alone will develop into a new and more effective therapy, or whether these approaches will supplement and improve chemo and radiation therapy.
MEDICA.de; Source: Max-Delbrück-Centrum für Molekulare Medizin (MDC) Berlin-Buch